Semnur Pharmaceuticals, Inc. Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount
Semnur Pharmaceuticals, Inc. (SMNR) reported Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount of $24.10 million for the 12-month period ending 2025-12-31, per its S-1 filed 2026-05-12.
Financial Statements › Notes › Income Taxes › Components of Deferred Tax Assets
us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount · last filed 2026-05-12
| Period end | Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount 12 month |
|---|---|
| 2025-12-31 | $24.10M S-1 · filed 2026-05-12 |
| 2024-12-31 | $800.00K S-1 · filed 2026-05-12 |